2921676-04-0
Chemical Structure
Pasritamig
Synonym(s): JNJ-78278343; KLCB-245
- CAS No.: 2921676-04-0
- Formula:N/A
- Molecular Weight:(124.81 kDa)
SMILES: [Pasritamig]
Biological Activity: Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pasritamig | 97.76% | Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Stein MN, et al. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol. 2025;43(22):2515-2526. [Content Brief]
- [2]. Cui J, et al. 298eP Preliminary results of a multicenter, open-label, randomized, phase II trial (ALTER-PA-001 trial) of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer[J]. Immuno-Oncology and Technology, 2025, 28.
- [3]. Meng L, Yang Y, Mortazavi A, Zhang J. Emerging Immunotherapy Approaches for Treating Prostate Cancer. Int J Mol Sci. 2023 Sep 20;24(18):14347. [Content Brief]
- [4]. Wang X, et al. 305eP Camrelizumab combined with nab-paclitaxel as second-line therapy for advanced biliary tract cancer (BTC): A real-world study[J]. Immuno-Oncology and Technology, 2025, 28.
Keywords
